COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer

British Journal of Cancer

Volumn 94, Issue 8, 2006, Pages 1154-1163

  Timoshenko, A V ^a   Chakraborty, C ^a   Wagner, G F ^a   Lala, P K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer; COX 2; EP receptors; Lymphangiogenesis; VEGF C

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CONCANAVALIN A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIAMINOBENZIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR; SMALL INTERFERING RNA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HS578T; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN T 47D; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; GLYCOPROTEINS; HUMANS; IMIDAZOLES; LYMPHANGIOGENESIS; MOLECULAR SEQUENCE DATA; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 33646163924     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603067     Document Type: Article

References (57)

1. Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclo-oxygenase-2 gene. Biochem J 302: 723-727
2. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7: R422-R435
3. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL, Jackson DG (2002) Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315-1320
4. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690
5. Byeon JS, Jung HY, Lee YJ, Lee D, Lee GH, Myung SJ, Yang SK, Hong WS, Kim JH, Min YI, Kim JS (2004) Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol 19: 648-654
6. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994
7. 2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 65: 4496-4499
8. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K (1997) Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 272: 25176-25183
9. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705-4708
10. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL (1994a) A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47: 151-168
11. Coleman RA, Smith WL, Narumiya S (1994b) VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229
12. 3-mediated activation of nuclear factor-κB. J Biol Chem 280: 12145-12151
13. Cunnick GH, Jiang WG, Gomez KF, Mansel RE (2001) Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun 288: 1043-1046
14. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O'Dwyer ST, Jayson GC (2003a) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89: 426-430
15. Duff SE, Li C, Renehan A, O'Dwyer ST, Kumar S (2003b) Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol 22: 339-343
16. Enholm B, Paavonen K, Ristimäki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475-2483
17. Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T (2004) Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer 91: 466-469
18. Harris RE (2003) COX-2 blockage in cancer prevention and therapy. New Jersey: Humana Press
19. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764
20. Hull MA, Ko SCW, Hawcroft G (2004) Prostaglandin EP receptors. Targets for treatment and prevention of colon cancer? Mol Cancer Ther 3: 1031-1039
21. Kimura Y, Watanabe M, Ohga T, Saeki H, Kakeji Y, Baba H, Maehara Y (2003) Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 10: 1747-1751
22. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K (2001) Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 66: 159-164
23. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, Mokbel K (2002) The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18: 237-241
24. Kyzas PA, Stefanou D, Agnantis NJ (2005) COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol 18: 153-160
25. Lala PK, Al-Mutter N, Orucevic A (1997) Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 73: 371-380
26. Lala PK, Saarloos MN (1994) Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In Prostaglandin inhibitors in tumor immunology and immunotherapy Harris JE, Braun DP, Anderson KM (eds) pp 187-227. Boca Raton: CRC Press
27. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569
28. Liu XH, Rose DP (1996) Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125-5127
29. Mattila MMT, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Härkönen PL (2002) VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 98: 946-951
30. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2003) Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16: 309-314
31. Nakashima T, Kondoh S, Kitoh H, Ozawa H, Okita S, Harada T, Shiraishi K, Ryozawa S, Okita K (2003) Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med 11: 33-39
32. O-charoenrat P, Rhys-Evans P, Eccles SA (2001) Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568
33. Ohshiba T, Miyaura C, Ito A (2003) Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 300: 957-964
34. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K (2004) Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95: 32-39
35. Parrett ML, Harris RE, Jorder FA, Ross MS, Clausen KP, Robertson FK (1997) Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10: 503-507
36. Ristimäki A, Garfinkel S, Wessendorf J, Maciag T, Hla T (1994) Induction of cyclooxygenase-2 by interleukin-1α. Evidence for post-transcriptional regulation. J Biol Chem 269: 11769-11775
37. Ristimäki A, Narko K, Enholm B, Joukov V, Alitalo K (1998) Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 273: 8413-8418
38. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M (1980) Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061-1070
39. Rozic JG, Chakraborty C, Lala PK (2001) Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506
40. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K (2004) Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395
41. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081
42. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645
43. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML (2004) Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64: 554-564
44. Tamura M, Ohta Y (2003) Serum vascular endothelial growth factor-C level in patients with primary non-small cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 98: 1217-1222
45. Timoshenko AV, Lala PK, Chakraborty C (2004) PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int J Cancer 108: 384-389
46. 2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289: 265-274
47. Tomita M, Li X, Okada Y, Woodiel FN, Young RN, Pilbeam CC, Raisz LG (2002) Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 30: 159-163
48. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML (2003) Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β1. A critical role of p38/nuclear factor-κB signaling pathway. J Biol Chem 278: 5750-5759
49. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716
50. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey 3rd TJ (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990
51. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10: 7965-7971
52. Vleugel MM, Bos R, van der Groep P, Greijer AE, Shvarts A, Stel HV, van der Wall E, van Diest PJ (2004) Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 57: 746-751
53. von Rahden BHA, Stein HJ, Puhringer F, Koch I, Langer R, Piontek G, Siewert JR, Hofler H, Sarbia M (2005) Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65: 5038-5044
54. Wang D, Dubois RN (2004) Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31(Suppl 3): 64-73
55. Williams CS, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL, Jackson DG (2003) Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 200: 195-206
56. Xu JW, Ikeda K, Yamori Y (2004) Upregulation of endothelial nitric oxide synthase by cyanidin-3-glucoside, a typical anthocyanin pigment. Hypertension 44: 217-222
57. Zhang DH, Salto-Tellez M, Chiu LL, Shen L, Koay ESC (2003) Tissue microarray study for classification of breast tumors. Life Sci 73: 3189-3199